Wednesday, May 8, 2024
5/8/2024
PROJECT SUMMARY/ABSTRACT Prostate cancer is the most common and second deadliest non-skin cancer in American men, accounting for 26% of new cancer diagnoses and 9% of cancer deaths in men. Active surveillance, radical prostatectomy and radiotherapy are commonly used treatments for clinically localized prostate cancer. However, current risk stratification methods cannot be used effectively to avoid subjecting patients with clinically indolent cancers to unnecessary interventions, causing significant morbidity and cost. The primary components currently involved in screening are the digital rectal exam (DRE) and serum biomarkers, such as PSA, PCA3, PHI, and 4Kscore. Unfortunately, despite advances in these tests, overdiagnosis remains a major problem due to limited specificity. As a result, 90% of patients diagnosed with prostate cancer receive treatment, even though up to 60% of those patients could be candidates for active surveillance. Such treatment often results in long-term reductions in functional outcomes. The research objective of this R01 is to develop novel markers and models to both more accurately detect aggressive cancer and to forecast its arrival. Using a large cohort of patients, we first plan to identify novel pathomic and germline features that indicate the presence of aggressive cancer or its precursors. We then plan to implement an integrative graph convolutional network (GCN) combined with a convolutional neural network (CNN) to generate new multi-modal representations of underlying cancer state within the entire prostate. The framework will combine multiparametric magnetic resonance imaging (mpMRI), digital histology images, germline features, biomarkers, and other predictors. We will also implement a baseline nomogram risk model for comparison, as well as several new nomogram models that incorporate our newly identified features.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
